Company profile
NeoGenomics, Inc.
NASDAQ: NEO · Healthcare · Medical - Diagnostics & Research
#183 of 1,422 Healthcare companies by revenue56th-percentile growth
EA Score
72BFH 68DQ 76GM 71SS 81
v0.1 · 65/100 weight · provisional
↑ filing timeliness, growth stability · ↓ disclosure history, revenue growth (YoY)
Methodology →Revenue TTM
$746.0M
Rev growth YoY (TTM)
+10.9%
Net income (FY)
-$108.0M
Employees
2,500
as of 2026-08-12
Market cap
$424.7M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$727.3M$727.3M2025
Net income-$108.0M-$108.0M2025
Operating income-$115.9M-$115.9M2025
Total assets$1.4B$1.4B2025
Liabilities$523.3M$523.3M2025
Equity$836.6M$836.6M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Commercial Insurance100%
By geography
Not disclosed.
The read
What is NeoGenomics, Inc.’s revenue?
NeoGenomics, Inc. booked $727.3M in FY2025 revenue, growing 10% year over year — about the middle of the pack among Healthcare companies we track, at a -14.9% net margin.
Peers · Healthcare
iRhythm Technologies, Inc.75B+Emergent BioSolutions Inc.69BRepligen Corporation82B+Pacira BioSciences, Inc.78B+Amphastar Pharmaceuticals, Inc.77B+Supernus Pharmaceuticals, Inc.76B+Neighbors
Lee →Key facts
CEOAnthony Zook
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersFort Myers, FL
ExchangeNASDAQ: NEO
Employees2,500
IPO date2004-03-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.